A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Trial Profile

A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs IRX 2 (Primary) ; IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Omeprazole
  • Indications Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 30 Oct 2022 to 8 Nov 2022.
    • 15 Nov 2017 Planned primary completion date changed from 30 Oct 2021 to 8 Nov 2021.
    • 15 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top